N-gamboyl Gemcitabine Inhibits Tumor Cells Proliferation and Migration

• Published in: 东华大学学报（英文版） Vol. 40; no. 4; pp. 377 - 383
• Main Authors: PEI Yifei, DENG Min, JIANG Yuxin, SHAO Zhiyu, WANG Hongsheng
• Format: Journal Article
• Language: English
• Published: Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine,College of Biological Science and Medical Engineering,Donghua University,Shanghai 201620,China 31.08.2023; College of Chemistry and Chemical Engineering,Donghua University,Shanghai 201620,China%The First Hospital of Jiaxing,Jiaxing Key Laboratory of Virus-Related Infectious Diseases,Jiaxing University,Jiaxing 314001,China%College of Chemistry and Chemical Engineering,Donghua University,Shanghai 201620,China%Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine,College of Biological Science and Medical Engineering,Donghua University,Shanghai 201620,China
• Subjects: N-gamboyl gemcitabine(GAG); gambogic acid(GA); gemcitabine(GEM); antitumor
• ISSN: 1672-5220
• DOI: 10.19884/j.1672-5220.202303005

R91; Gambogic acid(GA)is a natural substance with a good antitumor effect,but it is too lipophilic to be metabolized and excreted,thus accumulating in the body.Gemcitabine(GEM),one of the first-line antitumor drugs,has high hydrophilicity,which greatly shortens its half-life in vivo.We previously reported a compound named N-gamboyl gemcitabine(GAG),derived from the condensation of GEM and GA,whose hydrophilicity is better than GA and stability is better than GEM.Here,the antitumor performance of GAG was investigated for the first time by using several common tumor cell lines as tumor models.The results of in vitro study showed that GAG significantly inhibited the proliferation and migration of the tumor cells.The IC50 values of GAG for the tumor cells were lower than those of GEM and GA.The present study suggests that GAG has a promising potential to be developed into a broad-spectrum antitumor drug.